Reference

Treatment of pulmonary hypertension: endothelin-receptor antagonists

All Rights Reserved. Treatment of pulmonary hypertension: endothelin-receptor antagonists. Hoeper, Marius M. (Abteilung Pneumologie, Medizinische Hochschule Hannover, Hannover D-30623, Germany). Deutsche Medizinische Wochenschrift, 131(49, Suppl.There are some reagents with their cas registry numbers 177036-94-1 and 184036-34-8 are used in this study. 9), S308-S310 (German) 2006 Georg Thieme Verlag. CODEN: DMWOAX. ISSN: 0012-0472. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review on treatment of pulmonary arterial hypertension by endothelin receptor antagonists. Biol. of the endothelin system, pathophysiol., and prognostic significance of endothelin-1 in pulmonary hypertension are described. Therapy of idiopathic pulmonary arterial hypertension and other types of pulmonary hypertension by the dual endothelin-receptor antagonist bosentan and treatment of pulmonary arterial hypertension with selective endothelin-A receptor antagonists (sitaxsentan and ambrisentan) are discussed. .